ANL

Adlai Nortye (ANL)

About Adlai Nortye (ANL)

Adlai Nortye Ltd. is a clinical-stage biopharmaceutical company, which engages in the provision of development of cancer therapies for patients with stages of tumors. It offers AN0025, a clinical stage, potential EP4 antagonist designed to modulate tumor microenvironment. The company was founded on May 9, 2018, and is headquartered in Hangzhou, China.

Details

Daily high

$14.70

Daily low

$13.00

Price at open

$14.00

52 Week High

$17.25

52 Week Low

$0.88

Market cap

475.2M

Dividend yield

0.00%

Volume

269,999

Avg. volume

214,778

P/E ratio

-13.75

Adlai Nortye News